Short Interest in Itonic Holdings Ltd. (NASDAQ:ITOC) Increases By 115.6%

Itonic Holdings Ltd. (NASDAQ:ITOC) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 344,406 shares, a growth of 115.6% from the April 15th total of 159,717 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average trading volume of 4,386,228 shares, the short-interest ratio is currently 0.1 days.

Itonic Trading Down 2.3%

Shares of NASDAQ:ITOC traded down $0.01 during trading on Friday, reaching $0.30. The company had a trading volume of 116,451 shares, compared to its average volume of 2,518,439. Itonic has a twelve month low of $0.25 and a twelve month high of $32.00. The business’s fifty day moving average is $0.33.

Itonic (NASDAQ:ITOC) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.23 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Itonic in a research report on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Itonic Company Profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.